Merck - Test of Support LikelyThe lack of strength of the recent rally and the downward trend suggests a short-term test of support.
MRK trade ideas
Rounded top Chart Pattern of MRK:What Is A Rounding Top Chart Pattern ? A chart pattern used in technical analysis which is identified by price movements that, when graphed, form the shape of an upside down “U”. A rounding top may form at the end of an extended upward trend and indicates a reversal in the long-term price movement.
A rounding top represents a sell signal . The initial upwards trend becomes exhausted as the demand for the stock dries up.
The reversal to the downward slope of the rounding top indicates that demand has tapered off and a surplus supply is present, basically there are more sellers than buyers.
The price will be move so far in-case of breakout any side cause, the pattern is too tight.
Pullback at a minimumWe have Kumo resistance as well as a prior swing high. This almost looks like a Inv HnS forming, and so I expect at least a pullback to form the right shoulder. At best, it's a complete capitulation.
MRK cup and handleMonthly cup and handle, looks nice. Thanks to yamgaexpress for pointing this out..
MRK Strong Downtrend Lower targets for next week, got upgraded today and then smacked down lets see if we can make more lows with the selling pressure.
Potential breakout, major support/trend line to be testedThis stock has been showing a consistent uptrend setting higher highs and higher lows. It is approaching it's key support with the RSI also showing it to be undervalued. Worth a look.
MRK-Short at 4 hr supply NYSE:MRK
MRK had a strong bearish correction at the start of the year and we believe that the stock price may continue to fall after a period of bullish rebound in 4hr.
However, do take note that if the stock's bullish rise breaks the high, then we will see the stock return to the strong bullish impulse.
Short ConditionsAfter the failure of a key support(blue zone), we have a return to it
probability of falling is very high
But you can wait for formation of a revarsal pattern And then sell it.
Good luck
$MRK bullish divergence before earnings$MRK bullish divergence with RSI at 0.61 fibonacci retracement. Merck & Co Inc (MRK) is scheduled to announce its earnings on Wednesday, February 5 before market opens. Daily chart.
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
MRK - DAILY CHARTHi, today we are going to talk about Merck & Co. and its current landscape.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
